In the UK (58%) and US (55%), over half of participants reported that children were sometimes started on CF care pathways (Europe/RoW 41%), and this treatment did, or sometimes could, include CFTR modulators (UK 48%, US 38%) but this was rarely reported by participants from Europe/RoW (6%) (Table 5). This evidence concerns the gene CFTR and cystic fibrosis.